GhassanEEl-HaddadMD
Interventional Radiology • Tampa, FLSenior Member, Interventional Radiology, Section Head of Radionuclide Therapy Program, Moffitt Cancer Center Associate Professor, Radiology and Oncological Sciences, University of South Florida
Dr. El-Haddad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12902 Magnolia Dr
Tampa, FL 33612Phone+1 813-745-1598
Summary
- Dr. Ghassan El-Haddad is a radiologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Lebanese University School of Medicine and has been in practice 16 years. He specializes in nuclear medicine and vascular & interventional radiology.
Education & Training
University of Pennsylvania Health SystemFellowship, Interventional Radiology - Independent, 2011 - 2012
Quinnipiac University Frank H. Netter MD School of Medicine/St VIncent's Medical CenterResidency, Radiology-Diagnostic, 2008 - 2012- University of Pennsylvania Health SystemResidency, Nuclear Medicine, 2003 - 2006
SUNY Upstate Medical UniversityInternship, Internal Medicine, 2002 - 2003
Lebanese University School of MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2012 - 2026
LA State Medical License 2006 - 2012
PA State Medical License 2003 - 2012
MI State Medical License 2005 - 2009- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Radiology Interventional Radiology and Diagnostic Radiology
Clinical Trials
- Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma Start of enrollment: 2016 Mar 04
- Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver Start of enrollment: 2016 Mar 01
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2018 May 29
Publications & Presentations
PubMed
- 942 citationsLutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.Oliver Sartor, Johann S. de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann
The New England Journal of Medicine. 2021-06-23 - 4 citationsCirculating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients.Jonathan Alexander Chatzkel, Jesse Mocha, Johnna Smith, Jun-Min Zhou, Young Chul Kim
Future Science OA. 2020-01-01 - 1785 citationsPhase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan R. Strosberg, Ghassan El-Haddad, Edward M. Wolin, Andrew Eugene Hendifar, James C. Yao
The New England Journal of Medicine. 2017-01-11
Journal Articles
- Melanocortin 1 Receptor Targeted Alpha-Particle Therapy for Metastatic Uveal Melanoma.Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, Bhatt NB, Kock ND, Messina JL, Ruiz EE, Delva NC, Weaver A, Gibbons WR, Boulware DC, Khushalan..., J Nucl Med. 2019 Feb 7., 2/2019
Press Mentions
A Review of the VISION Trial: Lutetium-177-PSMA-617 Effective in Treating Metastatic Castration-Resistant Prostate CancerSeptember 10th, 2021
Professional Memberships
- Member
- Member
- Member
- Society of Nuclear Medicine and Molecular ImagingMember
- Cardiovascular and Interventional RadiologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
